Literature DB >> 21048308

1,2,3,4,6-Penta-O-galloly-beta-D-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1α and signaling in LNCaP prostate cancer cells.

Ki-Young Park1, Hyo-Jeong Lee, Soo-Jin Jeong, Hyo-Jung Lee, Hyun-Seok Kim, Sun-Hyung Kim, Sabina Lim, Ho-Cheol Kim, Junxuan Lü, Sung-Hoon Kim.   

Abstract

Hypoxia is the hallmark of solid tumors and contributes to tumor angiogenesis mainly through activation of the transcription factor hypoxia-inducible factor-1 (HIF-1). In addition to upregulating vascular endothelial growth factor (VEGF) in angiogenesis, HIF-1 plays critical roles in the metabolism, proliferation, metastasis, and differentiation of cancer cells. We and others have previously shown that 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) from Oriental herbal medicine possesses anti-angiogenic, anti-tumorigenic, and anti-diabetic activities. In the present study, we report that PGG inhibits hypoxia-induced protein accumulation, transcriptional activation, and mRNA expression of HIF-1α in LNCaP prostate cancer cells. PGG reduced cellular and secreted VEGF levels as well as mRNA expression in LNCaP cells. PGG suppressed capillary tube formation in human umbilical vein endothelial cells (HUVECs) maintained in conditioned medium of hypoxia-induced LNCaP cells, indicating that PGG has anti-angiogenic activity under hypoxic condition. Furthermore, PGG reduced expression of phosphoinositide 3-kinase (PI3K) as well as phosphorylation of AKT and mammalian target of rapamycin (mTOR), but not extracellular signal-regulated kinase (ERK) in LNCaP cells under hypoxic condition. Consistently, LY294002, a specific PI3K inhibitor, enhanced the inactivation of HIF-1α and AKT by PGG in LNCaP cells. Taken together, our results demonstrate that PGG inhibits hypoxia-mediated accumulation of HIF-1α as well as its downstream signaling to VEGF and PI3K/AKT/mTOR pathway in LNCaP prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21048308     DOI: 10.1248/bpb.33.1835

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.264


  6 in total

1.  Apoptotic and DNA Damage Effect of 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose in Cisplatin-Resistant Non-Small Lung Cancer Cells via Phosphorylation of H2AX, CHK2 and p53.

Authors:  Ji-Hyun Kim; Eunji Im; Jihyun Lee; Hyo-Jung Lee; Deok Yong Sim; Ji Eon Park; Chi-Hoon Ahn; Hyeon Hee Kwon; Bum Sang Shim; Bonglee Kim; Sung-Hoon Kim
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

Review 2.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

3.  Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells.

Authors:  Jimin Shin; Hyo-Jeong Lee; Deok-Beom Jung; Ji Hoon Jung; Hyo-Jung Lee; Eun-Ok Lee; Seok Geun Lee; Beom Sang Shim; Seung Hoon Choi; Seong Gyu Ko; Kwang Seok Ahn; Soo-Jin Jeong; Sung-Hoon Kim
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

4.  Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells.

Authors:  Seon-Ok Lee; Joo-Seok Kim; Myoung-Sun Lee; Hyo-Jeong Lee
Journal:  BMC Cancer       Date:  2016-08-31       Impact factor: 4.430

5.  Inhibition of Hypoxia Inducible Factor Alpha and Astrocyte-Elevated Gene-1 Mediates Cryptotanshinone Exerted Antitumor Activity in Hypoxic PC-3 Cells.

Authors:  Hyo-Jeong Lee; Deok-Beom Jung; Eun Jung Sohn; Hanna Hyun Kim; Moon Nyeo Park; Jae-Hwan Lew; Seok Geun Lee; Bonglee Kim; Sung-Hoon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-29       Impact factor: 2.629

Review 6.  Biological and biomedical functions of Penta-O-galloyl-D-glucose and its derivatives.

Authors:  Yanyan Cao; Klaus B Himmeldirk; Yanrong Qian; Yulin Ren; Ahmed Malki; Xiaozhuo Chen
Journal:  J Nat Med       Date:  2014-02-15       Impact factor: 3.192

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.